阿比多尔抗病毒研究进展  

Progress of Antiviral Research of Arbidol

作　　者：白镓玮 马承泰 魏捷[2] 吴淼[2] 杜贤进[1] BAI Jiawei;MA Chengtai;WEI Jie;WU Miao;DU Xianjin(Dept.of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,China;Dept.of Emergency,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院重症医学科,武汉430060 [2]武汉大学人民医院急诊科,武汉430060

出　　处：《中国医院用药评价与分析》2022年第4期508-512,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：北京协和医学基金会-睿E(睿意)急诊医学专项研究基金项目(No.R2019028)。

摘　　要：阿比多尔是一种非核苷类广谱抗病毒药,主要通过抑制病毒进入细胞和调节免疫发挥抗病毒作用。大量研究结果证实,阿比多尔对多种病毒具有抗病毒活性,包括DNA病毒和RNA病毒,包膜和非包膜病毒,但其在我国主要用于治疗由A型、B型流感病毒等引起的上呼吸道感染。新型冠状病毒肺炎(COVID-19)疫情暴发后,体内外实验结果证实,阿比多尔对新型冠状病毒(SARS-CoV-2)有明显抑制作用,使用阿比多尔可改善患者临床结局,但也有报道指出阿比多尔无确切疗效。阿比多尔作为一种潜在有效的抗病毒药还需大量临床实践证实。Arbidol is a kind of non-nucleoside broad-spectrum antiviral drugs,which plays an antiviral role mainly by inhibiting the entry of virus into cells and regulating immunity.A large number of experiments have confirmed the antiviral activity of arbidol against a variety of viruses,including DNA and RNA viruses,enveloped and non-enveloped viruses.In China,arbidol is mainly used for the treatment of upper respiratory tract infection caused by influenza A and B virus.After the outbreak of COVID-19 pandemic,the results of in vitro and in vivo experiments confirmed that arbidol has significant inhibitory effects on SARS-CoV-2,and the use of arbidol can improve the clinical outcomes of patients,yet there are also reports shows that arbidol has no definite curative efficacy.As a kind of potentially effective antiviral drugs,arbidol still needs a lot of clinical practice confirmation.

关 键 词：阿比多尔 抗病毒 流感病毒 新型冠状病毒肺炎 

分 类 号：R978.7[医药卫生—药品]